The patented revolutionary ForeCYTE Breast Health Test is designed for the early detection of precancerous breast conditions and the determination of the future risk of breast cancer. The ForeCYTE Test, which uses the patented, FDA-cleared MASCT Breast Health System to painlessly collect a tiny sample of nipple ductal fluid, is designed to be performed at the point of care in a non-invasive and highly sensitive manner.
According to Rick Simpson, CEO Diagnostic Test Group, LLC “The ForeCYTE Breast Health Test is a clear advancement in breast health that will help doctors save women’s lives and help us look forward to a future where we all can be fearless about breast cancer. The system is easy to operate and requires only 15 minutes of a patient’s time to collect a sample for testing. Healthcare providers will be better able to advise patients on prevention and management of their breast cancer risks.”
ForeCYTE is targeted for over 110 million women between the ages of 18 and 73 in the U.S. who can now obtain a simple test in their physician's office and learn their future risk of breast cancer up to eight years before mammography can pick it up. This kind of advanced information was created for cervical cancer by the Pap smear and was responsible for the 75% reduction in the incidence of cervical cancer. The ForeCYTE Breast Health Test has the potential to do the same for breast cancer.
Simpson has extended an open invitation to medical practitioners’
About Clarity Women's Health
Clarity Women's Health is a division of Diagnostic Test Group, LLC in Boca Raton, FL, and is a sales, marketing and branding company focused on the sale and distribution of its own Clarity brand of rapid and diagnostic tests, molecular tests, and diagnostic equipment utilized in physicians' offices, clinics, labs, urgent care centers and hospitals. DTG offers one of the largest lines of diagnostic tests in the industry supported by its own national sales force combined with in-house 24 hour customer service and tech support. Clarity products are available at most of the recognized national distributors. The ForeCYTE Breast Health Test will form the cornerstone of its newly created division, Clarity Women's Health.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
Make sure to visit Clarity Women’s Health during this year’s Pri-Med South Annual Conference (http://www.pri-
Questions. Please Contact:
Advertising & Marketing Limited
(for Clarity Women’s Health) 954-465-2099